Immunovant (IMVT) Q3 2026 earnings summary

Executive summary

• Reported positive phase 2 results for brepocitinib in cutaneous sarcoidosis, with 100% of high-dose patients achieving clinically meaningful improvement and strong safety profile.

• IMVT-1402 registrational trial in difficult-to-treat rheumatoid arthritis fully enrolled; topline data expected in H2 2026.

• Focused on developing IMVT-1402, a next-generation FcRn inhibitor, for autoimmune diseases, with ongoing trials in six indications and leveraging batoclimab insights.

• NDA for brepocitinib in dermatomyositis submitted; multiple pivotal studies across three indications ongoing or planned.

• $550 million raised in underwritten financing, extending cash runway to potential IMVT-1402 launch in Graves' disease.

Financial highlights

• R&D expense for the quarter was $165 million, with adjusted non-GAAP R&D at $147 million.

• Net loss for Q3 FY2026 was $110.6 million ($0.61 per share), compared to $111.1 million ($0.76 per share) in Q3 FY2025.

• Cash and cash equivalents totaled $994.5 million as of December 31, 2025, up from $714.0 million at March 31, 2025, primarily due to a $543.6 million equity offering.

• G&A expense was $175 million, with adjusted non-GAAP G&A at $71 million.

• Total non-GAAP net loss for the quarter was $167 million.

Outlook and guidance

• 2026 expected to be a catalyst-rich year with multiple pivotal readouts, including Brepo NIU phase 3 and phase 3 initiation in cutaneous sarcoidosis.

• Topline data for IMVT-1402 in D2T RA and CLE expected in H2 2026; Graves' disease and MG data expected in 2027.

• Existing cash is expected to fund operating expenses and capital requirements for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.

• Multiple NDA and BLA filings anticipated, with potential commercial launches in coming years.